{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:40:34Z","timestamp":1794328834389,"version":"4.9.0"},"reference-count":41,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The aging obstetric population, combined with more frequent myeloproliferative neoplasm (MPN) diagnoses in younger patients, will result in hematologic providers increasingly caring for MPN patients in pregnancy. There are special considerations that pertain to management of pregnancy in MPN patients. This includes increased risks of thrombosis and hemorrhage as well as pregnancy complications that are likely related to placental dysfunction associated with an MPN diagnosis, including preeclampsia, preterm delivery, and intrauterine growth restriction. Complicating these outcomes is the uncertainty of the safety of many commonly used drugs in MPNs in pregnancy and breastfeeding. Given the overall low incidence of pregnancy in MPNs, many guidelines are based on expert opinions and extrapolation from other high-risk pregnancy populations. In this case-based review, we summarize the literature on MPN pregnancy outcomes and synthesize recommendations to provide guidance on the antepartum and postpartum management of MPN patients. Special attention is also made to issues relevant to preconception, including fertility and the use of assisted reproductive technology.<\/jats:p>","DOI":"10.1182\/hematology.2024000578","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T15:05:09Z","timestamp":1733497509000},"page":"541-546","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Pregnancy: MPN management before, during, and after pregnancy"],"prefix":"10.1182","volume":"2024","author":[{"given":"Joan","family":"How","sequence":"first","affiliation":[{"name":"1 Division of Hematology, Brigham and Women's Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Hobbs","sequence":"additional","affiliation":[{"name":"2 Division of Oncology, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"issue":"3","key":"2024121115504455800_hem2024000578C1","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjh.14061","article-title":"Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic\/myeloproliferative neoplasms in the United States, 2001-12","volume":"174","author":"Srour","year":"2016","journal-title":"Br J Haematol"},{"issue":"3","key":"2024121115504455800_hem2024000578C2","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.stem.2021.02.001","article-title":"Reconstructing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms","volume":"28","author":"Van Egeren","year":"2021","journal-title":"Cell Stem Cell"},{"issue":"11","key":"2024121115504455800_hem2024000578C3","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1038\/bcj.2015.94","article-title":"Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia","volume":"5","author":"Barbui","year":"2015","journal-title":"Blood Cancer J"},{"issue":"3","key":"2024121115504455800_hem2024000578C4","first-page":"CD010813","article-title":"Combined oral contraceptives: venous thrombosis","volume":"2014","author":"de Bastos","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"22","key":"2024121115504455800_hem2024000578C5","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1182\/bloodadvances.2023010177","article-title":"American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing","volume":"7","author":"Middeldorp","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"2024121115504455800_hem2024000578C6","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/s41375-024-02216-8","article-title":"Childbirth rates in women with myeloproliferative neoplasms","volume":"38","author":"Landtblom","year":"2024","journal-title":"Leukemia"},{"issue":"21","key":"2024121115504455800_hem2024000578C7","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2017-03-771857","article-title":"Adverse effect of hydroxyurea on spermatogenesis in patients with sickle cell anemia after 6 months of treatment","volume":"130","author":"Berthaut","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2024121115504455800_hem2024000578C8","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/bjh.16976","article-title":"Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide","volume":"191","author":"Pecker","year":"2020","journal-title":"Br J Haematol"},{"key":"2024121115504455800_hem2024000578C9","article-title":"Package insert","author":"Pegasys","year":"2011","journal-title":"Genentech"},{"issue":"9","key":"2024121115504455800_hem2024000578C10","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/aogs.13147","article-title":"Thromboembolism and in vitro fertilization - a systematic review","volume":"96","author":"Sennstr\u00f6m","year":"2017","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"22","key":"2024121115504455800_hem2024000578C11","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1182\/bloodadvances.2018024802","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy","volume":"2","author":"Bates","year":"2018","journal-title":"Blood Adv"},{"issue":"9","key":"2024121115504455800_hem2024000578C12","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/blood.2023020729","article-title":"How I treat myeloproliferative neoplasms in pregnancy","volume":"143","author":"Robinson","year":"2024","journal-title":"Blood"},{"issue":"10","key":"2024121115504455800_hem2024000578C13","doi-asserted-by":"crossref","first-page":"e1912666","DOI":"10.1001\/jamanetworkopen.2019.12666","article-title":"Association of treatments for myeloproliferative neoplasms during pregnancy with birth rates and maternal outcomes: a systematic review and meta-analysis","volume":"2","author":"Maze","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2024121115504455800_hem2024000578C14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/bjh.14289","article-title":"Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study","volume":"175","author":"Alimam","year":"2016","journal-title":"Br J Haematol"},{"issue":"5","key":"2024121115504455800_hem2024000578C15","doi-asserted-by":"crossref","first-page":"e882","DOI":"10.1097\/HS9.0000000000000882","article-title":"Outcome of 129 pregnancies in polycythemia vera patients: a report of the European LeukemiaNET","volume":"7","author":"Wille","year":"2023","journal-title":"Hemasphere"},{"issue":"1","key":"2024121115504455800_hem2024000578C16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/bjh.17626","article-title":"Pregnancy in patients with myelofibrosis: Mayo-Florence series of 24 pregnancies in 16 women","volume":"195","author":"Gangat","year":"2021","journal-title":"Br J Haematol"},{"issue":"3","key":"2024121115504455800_hem2024000578C17","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/ajh.26067","article-title":"Myeloproliferative neoplasms and pregnancy: overview and practice recommendations","volume":"96","author":"Gangat","year":"2021","journal-title":"Am J Hematol"},{"issue":"10","key":"2024121115504455800_hem2024000578C18","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1038\/s41375-022-01688-w","article-title":"Pregnancy and childbirth outcomes in women with myeloproliferative neoplasms-a nationwide population-based study of 342 pregnancies in Sweden","volume":"36","author":"Landtblom","year":"2022","journal-title":"Leukemia"},{"issue":"8","key":"2024121115504455800_hem2024000578C19","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1182\/blood-2016-09-728006","article-title":"Risk of venous thromboembolism in pregnant women with essential thrombocythemia: a systematic review and meta-analysis","volume":"129","author":"Skeith","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2024121115504455800_hem2024000578C20","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1370\/afm.668","article-title":"Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians","volume":"5","author":"Snow","year":"2007","journal-title":"Ann Fam Med"},{"issue":"11","key":"2024121115504455800_hem2024000578C21","doi-asserted-by":"crossref","first-page":"e443","DOI":"10.3324\/haematol.2015.131458","article-title":"Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia","volume":"100","author":"Rumi","year":"2015","journal-title":"Haematologica"},{"issue":"2","key":"2024121115504455800_hem2024000578C22","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1182\/blood-2007-01-071068","article-title":"Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V&gt;F) mutation","volume":"110","author":"Passamonti","year":"2007","journal-title":"Blood"},{"key":"2024121115504455800_hem2024000578C23","doi-asserted-by":"crossref","first-page":"106459","DOI":"10.1016\/j.leukres.2020.106459","article-title":"Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia","volume":"98","author":"How","year":"2020","journal-title":"Leuk Res"},{"issue":"1","key":"2024121115504455800_hem2024000578C24","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1097\/AOG.0000000000002708","article-title":"ACOG Committee Opinion No. 743: low-dose aspirin use during pregnancy","volume":"132","year":"2018","journal-title":"Obstet Gynecol"},{"issue":"5","key":"2024121115504455800_hem2024000578C25","doi-asserted-by":"crossref","first-page":"E114","DOI":"10.1002\/ajh.25748","article-title":"Pregnancy outcomes in myeloproliferative neoplasms: a Mayo Clinic report on 102 pregnancies","volume":"95","author":"Gangat","year":"2020","journal-title":"Am J Hematol"},{"issue":"3","key":"2024121115504455800_hem2024000578C26","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s11239-018-1663-9","article-title":"The course of acquired von Willebrand syndrome during pregnancy among patients with essential thrombocytosis","volume":"46","author":"Rottenstreich","year":"2018","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"2024121115504455800_hem2024000578C27","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2005-02-0626","article-title":"Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy","volume":"106","author":"Greer","year":"2005","journal-title":"Blood"},{"key":"2024121115504455800_hem2024000578C28","unstructured":"National Comprehensive Cancer Network. Myeloproliferative Neoplasms Version 2.2022. www.nccn.org\/professionals\/physician_gls\/pdf\/mpn.pdf. Accessed 2April2022."},{"issue":"5","key":"2024121115504455800_hem2024000578C29","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.3324\/haematol.2015.139691","article-title":"Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series","volume":"101","author":"Beauverd","year":"2016","journal-title":"Haematologica"},{"issue":"12","key":"2024121115504455800_hem2024000578C30","first-page":"e20449","article-title":"High rate of obstetric complications in patients with essential thrombocythemia","volume":"13","author":"\u0130skender","year":"2021","journal-title":"Cureus"},{"issue":"5","key":"2024121115504455800_hem2024000578C31","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s00432-020-03430-4","article-title":"Interferon alpha for essential thrombocythemia during 34 high-risk pregnancies: outcome and safety","volume":"147","author":"Schrickel","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"2024121115504455800_hem2024000578C32","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/ejh.13627","article-title":"The management, outcome, and postpartum disease course of 41 pregnancies in 20 women with polycythemia vera","volume":"107","author":"Wille","year":"2021","journal-title":"Eur J Haematol"},{"key":"2024121115504455800_hem2024000578C33","article-title":"Package insert","author":"Anagrelide","year":"2018"},{"key":"2024121115504455800_hem2024000578C34","article-title":"Package insert","author":"Ruxolitinib","year":"2021"},{"key":"2024121115504455800_hem2024000578C35","article-title":"Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys)","volume":"19","author":"Okikiolu","year":"2023","journal-title":"Leuk Res Rep"},{"issue":"1","key":"2024121115504455800_hem2024000578C36","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3390\/hematolrep15010018","article-title":"A case report of ropeginterferon alfa-2b for polycythemia vera during pregnancy","volume":"15","author":"Bang","year":"2023","journal-title":"Hematol Rep"},{"key":"2024121115504455800_hem2024000578C37","article-title":"Drugs and Lactation Database (LactMed\u00ae)","author":"Peginterferon Alfa","year":"2006"},{"key":"2024121115504455800_hem2024000578C38","article-title":"Drugs and Lactation Database (LactMed\u00ae)","author":"Hydroxyurea","year":"2006"},{"key":"2024121115504455800_hem2024000578C39","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.leukres.2019.04.003","article-title":"Management and outcome of 11 pregnancies in women with polycythemia vera","volume":"81","author":"Elli","year":"2019","journal-title":"Leuk Res"},{"issue":"1","key":"2024121115504455800_hem2024000578C40","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/14767058.2018.1484097","article-title":"Management and outcomes of 27 pregnancies in women with myeloproliferative neoplasms","volume":"33","author":"Lapoirie","year":"2020","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"1","key":"2024121115504455800_hem2024000578C41","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/jha2.622","article-title":"Impact of mutations on pregnancy outcome in patients with myeloproliferative neoplasms","volume":"4","author":"Maze","year":"2023","journal-title":"EJHaem"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/541\/2346409\/541how.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/541\/2346409\/541how.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T20:19:12Z","timestamp":1733948352000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2024\/1\/541\/526208\/Pregnancy-MPN-management-before-during-and-after"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,6]]},"published-print":{"date-parts":[[2024,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2024000578","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12,6]]},"published":{"date-parts":[[2024,12,6]]}}}